Company news

Eli Lilly And Company (NYSE:LLY) news

Eli Lilly And Company news releases on 6ix. Latest, Oct 9, 2026: New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance…

Eli Lilly And Company (NYSE:LLY) news

Press releases & updates

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL

LILLY PULITZER SUPPORTS THE PINK AGENDA WITH 'PETALS WITH A PURPOSE' PRINT CAPSULE FOR BREAST CANCER AWARENESS MONTH

Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease

EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes

New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis

Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison

Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs

FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata

U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020

U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight

Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity

Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases

FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes

Eli Lilly and Company - Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study

Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study

Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Veeva Vault CRM Selected by Eli Lilly and Company

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

Lilly confirms date and conference call for second-quarter 2026 financial results announcement

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

The Biotech Growth Trust PLC - Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc.

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

/C O R R E C T I O N -- Eli Lilly and Company/

Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment

Health Canada approves Mounjaro® (tirzepatide) for use in children 10 years and older living with type 2 diabetes

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios in Mainland China

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI

NYSE Content Update: Abridge Partners with Eli Lilly, Nvidia to Improve Healthcare

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options

Lilly declares third-quarter 2026 dividend

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable